The miR-193a-3p regulated PSEN1 gene suppresses the multi-chemoresistance of bladder cancer

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 3, 2015, Pages 520-528

  Deng, Hui ^a   Lv, Lei ^a   Li, Yang ^b   Zhang, Cheng ^c   Meng, Fang ^a   Pu, Youguang ^a   Xiao, Jun ^d   Qian, Liting ^a   Zhao, Weidong ^a   Liu, Qi ^e   Zhang, Daming ^c   Wang, Yingwei ^c   Zhang, Hongyu ^f   He, Yinghua ^f   Zhu, Jingde ^a,f  

^a Cancer Epigenetics Program Anhui Cancer Hospital ^*  (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^d ANHUI PROVINCIAL HOSPITAL   (China)

^e HARBIN INSTITUTE OF TECHNOLOGY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bladder cancer; Chemoresistance; DNA damage response pathway; MiR 193a 3p; PSEN1

Indexed keywords

MICRORNA; MICRORNA 193A 3P; PRESENILIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN193 MICRORNA, HUMAN; PSEN1 PROTEIN, HUMAN; RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CONTROLLED STUDY; DNA DAMAGE; GENE OVEREXPRESSION; GENE REPRESSION; MOUSE; NONHUMAN; BIOSYNTHESIS; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; NEOPLASM PROTEINS; PRESENILIN-1; RNA, NEOPLASM; URINARY BLADDER NEOPLASMS;

EID: 84920263435     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.12.014     Document Type: Article

References (42)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Burger M., Catto J.W., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., Kassouf W., Kiemeney L.A., La Vecchia C., Shariat S. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 2013, 63(2):234-241.
3. von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005, 23:4602-4608.
4. Chang J.S., Lara P.N., Pan C.-X. Progress in personalizing chemotherapy for bladder cancer. Adv. Urol. 2012, 2012.
5. Gordon R.R., Nelson P.S. Cellular senescence and cancer chemotherapy resistance. Drug Resist. Updat. 2012, 15:123-131.
6. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
7. Martin J.J., Briz O., Monte M.J., Blazquez A.G., Macias R.I. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr. Cancer Drug Targets 2012, 12:402-438.
8. Li F., Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta (BBA) - Rev. Cancer 2010, 1805:167-180.
9. Capaccione K.M., Pine S.R. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 2013, 34:1420-1430.
10. Abbotts R., Thompson N., Madhusudan S. DNA repair in cancer: emerging targets for personalized therapy. Cancer Manag. Res. 2014, 6:77.
11. Landriscina M., Maddalena F., Laudiero G., Esposito F. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid. Redox Signal. 2009, 11:2701-2716.
12. Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem. Biodivers. 2010, 7:543-566.
13. Sau A., Pellizzari Tregno F., Valentino F., Federici G., Caccuri A.M. Glutathione transferases and development of new principles to overcome drug resistance. Arch. Biochem. Biophys. 2010, 500:116-122.
14. Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204:216-237.
15. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92:1295-1302.
16. Tan B., Piwnica-Worms D., Ratner L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 2000, 12:450-458.
17. Jedlitschky G., Leier I., Buchholz U., Barnouin K., Kurz G., Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996, 56:988-994.
18. To K. MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J. Biomed. Sci. 2013, 20:1-19.
19. Ma K., He Y., Zhang H., Fei Q., Niu D., Wang D., Ding X., Xu H., Chen X., Zhu J. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J. Biol. Chem. 2012, 287:5639-5649.
20. Lv H.D.L., Li Y., Zhang C., Liu X., Liu Q., Zhang D., Wang L., Pu Y., Zhang H., He Y., Wang Y., Yu Y., Yu T., Zhu J. The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell Death Dis. 2014, 5:e1402.
21. Deng H., Lv L., Li Y., Zhang C., Meng F., Pu Y., Xiao J., Qian L., Zhao W., Liu Q., Zhang D., Wang Y., Zhang H., He Y., Zhu J. miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the Oxidative Stress pathway. Mol Cancer 2014, 13:234.
22. Lv L., Li Y., Deng H., Zhang C., Pu Y., Qian L., Xiao J., Zhao W., Liu Q., Zhang D., Wang Y., Zhang H., He Y., Zhu J. MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett. 2014, pii: S0304-3835(14)00656-9.
23. Brunkan A., Goate A. Presenilin function and γ-secretase activity. J. Neurochem. 2005, 93:769-792.
24. Bertram L., Lill C.M., Tanzi R.E. The genetics of Alzheimer disease: back to the future. Neuron 2010, 68:270-281.
25. Chávez-Gutiérrez L., Bammens L., Benilova I., Vandersteen A., Benurwar M., Borgers M., Lismont S., Zhou L., Van Cleynenbreugel S., Esselmann H. The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J. 2012, 31:2261-2274.
26. Li J., Chen F., Cona M.M., Feng Y., Himmelreich U., Oyen R., Verbruggen A., Ni Y. A review on various targeted anticancer therapies. Target. Oncol. 2012, 7:69-85.
27. Heiser L.M., Sadanandam A., Kuo W.L., Benz S.C., Goldstein T.C., Ng S., Gibb W.J., Wang N.J., Ziyad S., Tong F., Bayani N., Hu Z., Billig J.I., Dueregger A., Lewis S., Jakkula L., Korkola J.E., Durinck S., Pepin F., Guan Y., Purdom E., Neuvial P., Bengtsson H., Wood K.W., Smith P.G., Vassilev L.T., Hennessy B.T., Greshock J., Bachman K.E., Hardwicke M.A., Park J.W., Marton L.J., Wolf D.M., Collisson E.A., Neve R.M., Mills G.B., Speed T.P., Feiler H.S., Wooster R.F., Haussler D., Stuart J.M., Gray J.W., Spellman P.T. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2724-2729.
28. Dou L., Li J., Zheng D., Li Y., Gao X., Xu C., Gao L., Wang L., Yu L. MicroRNA-205 downregulates mixed-lineage-AF4 oncogene expression in acute lymphoblastic leukemia. Oncol. Targets Ther. 2013, 6:1153.
29. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron 2003, 38:9-12.
30. Cho S., Lu M., He X., Ee P.-L.R., Bhat U., Schneider E., Miele L., Beck W.T. Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc. Natl. Acad. Sci. 2011, 108:20778-20783.
31. Zhang C.C., Yan Z., Zong Q., Fang D.D., Painter C., Zhang Q., Chen E., Lira M.E., John-Baptiste A., Christensen J.G. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl. Med. 2013, 2:233-242.
32. da Costa C.A., Sunyach C., Pardossi-Piquard R., Sévalle J., Vincent B., Boyer N., Kawarai T., Girardot N., George-Hyslop P.S., Checler F. Presenilin-dependent γ-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J. Neurosci. 2006, 26:6377-6385.
33. Checler F., Dunys J., Pardossi-Piquard R., Alves da Costa C. p53 is regulated by and regulates members of the γ-secretase complex. Neurodegener. Dis. 2010, 7:50-55.
34. Dunys J., Sevalle J., Giaime E., Pardossi-Piquard R., Vitek M.P., Renbaum P., Levy-Lahad E., Zhang Y.-w., Xu H., Checler F. p53-dependent control of transactivation of the Pen2 promoter by presenilins. J. Cell Sci. 2009, 122:4003-4008.
35. Dunys J., Kawarai T., Sevalle J., Dolcini V., George-Hyslop P.S., Da Costa C.A., Checler F. p53-dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the γ-secretase complex but is independent of its activity. J. Biol. Chem. 2007, 282:10516-10525.
36. Lee S., Das H.K. Inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) represses the expression of presenilin-1 by a p53-dependent mechanism. Brain Res. 2008, 1207:19-31.
37. Miyoshi K., Ohyagi Y., Sakae N., Motomura K., Ma L., Taniwaki T., Furuya H., Tabira T., Kira J.-i. Enhancement of activation of caspases by presenilin 1 gene mutations and its inhibition by secretase inhibitors. J. Alzheimers Dis. 2009, 16:551-564.
38. Ma L., Ohyagi Y., Miyoshi K., Sakae N., Motomura K., Taniwaki T., Furuya H., Takeda K., Tabira T., Kira J.-i. Increase in p53 protein levels by presenilin 1 gene mutations and its inhibition by secretase inhibitors. J. Alzheimers Dis. 2009, 16:565-575.
39. Hoffman B., Liebermann D. Apoptotic signaling by c-MYC. Oncogene 2008, 27:6462-6472.
40. Ho J.S., Ma W., Mao D.Y., Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol. Cell. Biol. 2005, 25:7423-7431.
41. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 2006, 6:663-673.
42. Yu J., Zhu T., Wang Z., Zhang H., Qian Z., Xu H., Gao B., Wang W., Gu L., Meng J., Wang J., Feng X., Li Y., Yao X., Zhu J. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin. Cancer Res. 2007, 13:7296-7304.